Creating a 3D model to study lung fibrosis similar to Idiopathic Pulmonary Fibrosis
Official title: Validation of an in vitro model of progressive fibrosis that mimics Idiopathic Pulmonary Fibrosis
Funded at University of California Los Angeles · NIH-10763361 · Data updated 2026-11-12
This study is creating a special 3D model of Idiopathic Pulmonary Fibrosis (IPF) using stem cells to better understand the disease and find new treatments that could work for different patients.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project start | February 15, 2021 |
| Project end | January 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $617,814 |
| NIH project number | 5U01HL153000-04 |
| Project ID | NIH-10763361 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with Idiopathic Pulmonary Fibrosis or those at risk due to genetic factors.
✕Less likely to help
Patients with other forms of lung disease or those without a diagnosis of pulmonary fibrosis may not benefit from this research.
What this research studies
This research focuses on developing a three-dimensional bioengineered model of Idiopathic Pulmonary Fibrosis (IPF) using human induced pluripotent stem cells. The model aims to replicate the progressive fibrosis seen in IPF, allowing researchers to study the disease's characteristics and test potential treatments. By utilizing specific lung cell types and architecture, the model will help in understanding the disease's heterogeneity and genetic risk factors. Ultimately, this research seeks to create a platform for high-throughput drug discovery tailored to individual patient needs.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized treatments for patients with Idiopathic Pulmonary Fibrosis.
How similar studies have gone: Previous research has shown promise in using bioengineered models for studying lung diseases, indicating that this approach could yield valuable insights.
Where this research is happening
-
University of California Los Angeles
Los Angeles, United States Active
Researchers
- Principal investigator: Gomperts, Brigitte N — University of California Los Angeles
- Study coordinator: Gomperts, Brigitte N
Related research
Other NIH-funded projects on the same topics.
-
Repurposing Pyrvinium as an Inhaled Therapy for Idiopathic Pulmonary Fibrosis
A patient-friendly look at a project trying to use an existing drug, pyrvinium, as an inhaled treatment option for idiopathic pulmonary fibrosis (IPF).
-
Screening new compounds to reverse gene signatures in IPF lungs
A researcher hopes to find compounds that reverse harmful gene changes in the lungs of people with idiopathic pulmonary fibrosis (IPF).
-
Unraveling IPF subtypes to guide prognosis and therapy
This grant aims to identify different IPF subtypes in the lung to improve how we predict outcomes and tailor treatments for people with IPF.
-
Novel antibody therapy to treat idiopathic pulmonary fibrosis
A small business gig is developing a targeted antibody drug (VSR-H5) to treat idiopathic pulmonary fibrosis in patients, aiming for better safety and effectiveness than current medicines.
-
Repurposing Vonoprazan as an inhaled therapy for IPF
A high-profile NIH grant is testing whether an existing drug, vonoprazan, can be inhaled to slow or reverse lung fibrosis in people with idiopathic pulmonary fibrosis (IPF).
-
Proteomic profile of IPF progression to help tailor treatments
A study will look for blood protein patterns that predict how IPF lung disease will progress in patients.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.